Advances in molecular-targeted therapies for gastric cancer and gastroesophageal junction adenocarcinoma
10.3969/j.issn.1000-8179.2015.23.892
- VernacularTitle:胃癌分子靶向治疗研究新进展
- Author:
Junhe LI
;
Jianping XIONG
- Publication Type:Journal Article
- Keywords:
gastric cancer;
gastroesophageal junction adenocarcinoma;
targets;
targeted therapy
- From:
Chinese Journal of Clinical Oncology
2015;(23):1118-1123
- CountryChina
- Language:Chinese
-
Abstract:
The prognosis of advanced gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma is poor. Although che-motherapy prolongs patient survival and improves quality of life to a greater extent best supportive care compared to, the median over-survival of patients with advanced gastric cancer is limited to approximately 7-10 months. With remarkable progress in the understand-ing of molecular mechanisms, molecular-targeted agents have been developed and evaluated in international randomized phaseⅢclini-cal trials. These agents may change the treatment mode of this disease. A ToGA study initially demonstrated that the trastuzumab, the monoclonal antibody of HER-2, as a molecular-targeted agent, in combination with chemotherapy, can prolong the overall survival of patients to 13.8 months. Several agents targeting angiogenesis, c-Met, PARP, and immunotherapy are currently subjected to clinical tri-als. This review summarizes the current status of molecular-targeted therapies for gastric cancer and GEJ adenocarcinoma.
